IGF-1 LR3 (1mg) Dosage Protocol
IGF-1 LR3 is a research peptide available in 1mg vial sizes. This protocol provides general guidance for reconstitution and dosing based on standard practices. Consult peer-reviewed literature for specific research applications.
Add 2.0 mL bacteriostatic water → 0.50 mg/mL concentration
Refer to specific research protocols for dosing guidance
At 0.50 mg/mL, calculate units based on desired dose
Lyophilized: freeze at −20°C; reconstituted: refrigerate at 2–8°C
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Week 1 | Starting dose | Per protocol |
| Week 2-4 | Maintenance dose | Per protocol |
| Week 5+ | Target dose | Per protocol |
- 1Draw 2.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall; avoid foaming
- 3Gently swirl/roll until dissolved (do not shake)
- 4Label and refrigerate at 2–8°C, protected from light
IGF-1 LR3 is a research peptide studied for various applications. Specific mechanisms and effects should be referenced from peer-reviewed literature. Detailed protocols are being developed based on published research.
- Research applications vary by peptide
- Refer to scientific literature for specific effects
- Consult research protocols for intended use
Lyophilized
Store at −20°C in dry, dark conditions
Reconstituted
Refrigerate at 2–8°C; avoid freeze-thaw cycles
Allow vials to reach room temperature before opening
- •Use new sterile insulin syringes for each injection
- •Rotate injection sites to reduce local irritation
- •Document daily dose and site rotation
- •This is for research purposes only
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.